Leading causes of castration-resistant prostate cancer

被引：0
|
作者：
Lu, Mingqian [1 ,2 ,3 ]
Lu, Hongda [4 ,5 ]
Kong, Qingzhi [4 ,5 ]
机构：
[1] Hubei Univ Chinese Med, Clin Med Coll, Wuhan 430061, Hubei Province, Peoples R China
[2] China Three Gorges Univ, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China
[3] Yichang Cent Peoples Hosp, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China
[4] Cent Hosp Wuhan, Dept Oncol, Wuhan 430014, Hubei Province, Peoples R China
[5] Canc Res Inst Wuhan, Wuhan 430014, Hubei Province, Peoples R China
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 04期
基金：
湖北省教育厅重点项目;
关键词：
androgen receptor; androgen receptor mutation; androgen receptor splicing; castration-resistant prostate cancer; neuroendocrine; progenitor cells; ANDROGEN RECEPTOR GENE; EPIDERMAL-GROWTH-FACTOR; ANTIANDROGEN WITHDRAWAL SYNDROME; TRANSGENIC MOUSE MODEL; TUMOR-CELL LINES; NEUROENDOCRINE DIFFERENTIATION; STEM-CELLS; SPLICE VARIANTS; FULL-LENGTH; CASODEX BICALUTAMIDE;
D O I：
10.1586/14737140.2015.1007957
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling. Even though androgen deprivation therapy shows its initial effectiveness on shrinking tumor size, it eventually fails to cure advanced PCa, which is determined by the occurrence of castration-resistance. In this review, we summarize the widely accepted mechanisms that account for castration-resistant PCa and discuss potential therapeutic targets.
引用
收藏
页码：425 / 432
页数：8
相关论文
共 50 条
  • [21] The DNA methylome of castration-resistant prostate cancer
    Kleb, Brittney N.
    Estecio, Marcos
    Zhang, Jiexin
    Tzelepi, Vasso
    Chung, Woonbok
    Maity, Sankar
    Logothetis, Christopher
    Troncoso, Patricia
    Navone, Nora
    Jelinek, Jaroslav
    Liang, Shoudan
    Issa, Jean-Pierre
    Aparicio, Ana
    CANCER RESEARCH, 2012, 72
  • [22] Enzalutamide in Castration-Resistant Prostate Cancer Reply
    Hussain, Maha
    Saad, Fred
    Sternberg, Cora N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1381 - 1381
  • [23] Predicting the future in castration-resistant prostate cancer
    Verhagen, Paul
    LANCET ONCOLOGY, 2009, 10 (03): : 201 - 202
  • [24] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
  • [25] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
  • [26] Cabazitaxel for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Sonpavde, Guru
    Sartor, Oliver
    FUTURE ONCOLOGY, 2011, 7 (01) : 15 - 24
  • [27] Visceral Disease in Castration-resistant Prostate Cancer
    Pezaro, Carmel J.
    Omlin, Aurelius
    Lorente, David
    Rodrigues, Daniel Nava
    Ferraldeschi, Roberta
    Bianchini, Diletta
    Mukherji, Deborah
    Riisnaes, Ruth
    Altavilla, Amelia
    Crespo, Mateus
    Tunariu, Nina
    de Bono, Johann S.
    Attard, Gerhardt
    EUROPEAN UROLOGY, 2014, 65 (02) : 270 - 273
  • [28] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13): : 1235 - 1246
  • [29] Pathophysiology and therapy of castration-resistant prostate cancer
    Merseburger, A. S.
    Kuczyk, M. A.
    Wolff, J. M.
    UROLOGE, 2013, 52 (02): : 219 - 225
  • [30] Castration-resistant Prostate cancer: Treatment is differentiated
    Wolff, Johannes M.
    AKTUELLE UROLOGIE, 2011, 42 (02)
12345